Introduction
Treatment of sepsis and septic shock in patients remains a great challenge, as evidenced by the fact that only a few treatment strategies and new therapies, such as activated protein C have found their way J Birnbaum, E Klotz, CD Spies et al. Combination therapy for endotoxaemia in rats into the clinic. 1 Many of the substances that have been tested in experimental and clinical settings have failed to be effective in clinical trials. Similarly, C1 esterase inhibitor (C1-INH), coagulation factor XIII (factor XIII), the free radical scavenger Nacetylcysteine (NAC) and the 21aminosteroid tirilazad mesylate (TM) have been the subject of different investigations into sepsis and multiple organ failure.
The important role that complement activation and the disturbance of the coagulation system play in the pathophysiological course of sepsis suggests that manipulating these cascades would seem logical. C1-INH has shown different beneficial effects on leucocyte activation, tissue perfusion and organ dysfunction in experimental and clinical sepsis settings. 2 -6 Factor XIII, a substance that is known to play a role in membrane stabilization, can also influence cell activation 7, 8 and protect endothelial barrier function. 9, 10 The release of different mediators also plays a pivotal role in sepsis. Oxygen free radicals in particular contribute to cell, tissue and organ damage. 11, 12 For this reason the free radical scavenger, NAC, has been used in different experimental and clinical settings because of its beneficial effects on tissue perfusion and tissue oxygenation. 13 -18 In addition, TM is an inhibitor of lipid peroxidation, and also has a potentially protective effect on global and regional circulation and on the endothelium, as well as reducing leucocyte activation and plasma extravasation in endotoxaemia and shock. 19 -23 As we have already observed beneficial effects from C1-INH, 4 factor XIII, 24 and also from NAC and TM 25 in a similar animal model, we were encouraged to test combinations of these substances. We, therefore, investigated the effects of a combination of C1-INH + factor XIII compared with a combination of NAC + TM on leucocyte activation, mesenteric plasma extravasation and plasma cytokine levels in a rat endotoxaemia model.
Materials and methods

ANIMALS
Forty male Wistar rats (200 -250 g, 6 -8 weeks old) were obtained from Tierzucht Schönwalde GmbH (Schönwalde, Germany) and housed in wood chip-bedded cages. The rats were acclimatized to the air-conditioned animal laboratory for 1 week prior to the experiment and kept on a 12 h light/dark cycle with free access to water (drinking bottle) and standard rat food (Altromin, Lage, Germany). Food was withdrawn 18 h prior to each experiment, but water remained freely available. The animal experiments were approved by the review board for the care of animal subjects (Landesamt für Arbeitsschutz, Gesundheitsschutz und technische Sicherheit Berlin) and performed in accordance with German legislation on the protection of animals.
ANAESTHESIA AND MONITORING
The animals were initially anaesthetized with 60 mg/kg pentobarbital (Sigma, Deisenhofen, Germany) injected intraperitoneally.
Anaesthesia was maintained for the duration of the experiment using 20 mg/kg per h pentobarbital IV. Fixation of the animals was carried out on a heating pad in a supine position, keeping the rectal body temperature between 36.5°C and 37.0°C. Tracheostomy was performed to maintain airway patency, and the animals were able to breathe room air spontaneously. The left jugular vein and carotid artery were cannulated with polyethylene catheters (PE-50; inner diameter, 0.58 mm; outer diameter, 
GENERAL PROTOCOLS
The 40 animals were randomly allocated into four groups of 10 animals each. All animals except those in the control (CON) group had endotoxaemia induced by continuous infusion of 5 mg/kg per h lipopolysaccharide (LPS) from Escherichia coli (serotype O55:B5; Sigma) over a 2-h period (overall dose 10 mg/kg body weight). The endotoxin infusion started at time point 0 h. Animals in the CON group did not receive endotoxin but were given an equivalent volume of normal saline (placebo infusion).
Animals in the LPS group only received endotoxin and no treatments. Animals in the C1-INH + factor XIII group received a combination of 100 U/kg body weight of C1-INH (Berinert ® HS; Aventis Behring, Marburg, Germany) and 50 U/kg body weight of factor XIII (Fibrogammin ® HS; Aventis Behring) administered by bolus IV infusion 30 min after starting the endotoxin infusion (time point 0.5 h). Animals in the NAC + TM group received a combination of 150 mg/kg body weight of NAC (Fluimucil Antidot ® ; Zambon GmbH, Kerpen, Germany) and 10 mg/kg body weight of TM (Freedox ® ; Pharmacia & Upjohn AG, Dübendorf, Germany) administered by bolus IV infusion 30 min after the start of endotoxin infusion (time point 0.5 h).
In all animals, we estimated leucocyte adherence to the venular endothelium and plasma extravasation into the mesentery by intravital fluorescence video microscopy (IVM) at time points 0 h (baseline), 1 h and 2 h after the start of endotoxin infusion.
Blood samples were drawn at time points 0 h, 1.5 h and 3 h after the start of endotoxin infusion for estimation of the plasma levels of tumour necrosis factor α (TNF-α), interleukin (IL)-1β, IL-6 and IL-10, and for white blood cell (WBC) determination (Technicon H1 cell counter; Bayer, Leverkusen, Germany).
Laparotomy for IVM was performed and followed by a stabilization period of 15 min. Subsequently, the endotoxin or placebo infusion was commenced (at time point 0 h). The abdomen was opened by a midline incision. A section of the distal small intestine orally from the ileocoecal valve was carefully placed on a specially designed microscope stage. During the entire in vivo microscopic procedure the intestine was superfused with crystalloid solution (Thomaejonin ® ; Thomae) at a constant temperature (37°C/97.8°F) to avoid dessication and exposure to ambient air.
The duration of each experiment, including induction of anaesthesia, did not exceed 4 h. At the end of the experiments, the animals were euthanized by a pentobarbital overdose.
INTRAVITAL FLUORESCENCE VIDEO MICROSCOPY
The IVM procedure was performed using an epifluorescent microscope (Axiotech Vario, filter block No. 20; Carl Zeiss, Oberkochen, Germany) with a 50 W HBO (Osram, Munich, Germany) short arc mercury lamp and equipped with a 10× long distance lens (10/0.5 Fluar ® ; Carl Zeiss) and a 20× water immersion lens (20/0.5 Achroplan ® ; Carl Zeiss) (mesentery: 40× water immersion, 40/0.8 Achroplan ® ; Carl Zeiss) and a 10× eyepiece. The images were transferred to a monitor (LDH 2106/00; Philips Electronics, Eindhoven, The Netherlands) by means of a J Birnbaum, E Klotz, CD Spies et al.
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video camera (FK 6990-IQ; Pieper, Schwerte, Germany) and were simultaneously recorded on a video cassette recorder (Panasonic AG 6200; Matsushita, Kadoma, Osaka, Japan) for off-line evaluation.
LEUCOCYTE-ENDOTHELIAL INTERACTION
Leucocytes were stained in vivo by IV injection of 0.2 ml of 0.017 g% rhodamine 6G (MW 479; Sigma) for contrast enhancement, enabling visualization in the microvasculature.
Mesenteric venules (diameter 25 -40 µm) were analysed. The flux of temporarily adherent rolling leucocytes was defined as the number of white cells moving at < 40% of the velocity of erythrocytes in the centre of the microvessels. It was estimated as the number of non-adherent leucocytes passing through the observed vessel segment within 30 s and was calculated as leucocytes/min. Firmly adherent leucocytes were defined in each vessel segment as those that did not move or detach from the endothelial lining within an observation period of 30 s. They are reported as the number of cells/mm 2 of endothelial surface, which was calculated from the diameter and length of the vessel segment studied, assuming cylindrical geometry. One vessel was evaluated three times in each animal. The evaluation of leucocyte adherence was performed in a blinded fashion.
PLASMA EXTRAVASATION
Plasma extravasation was estimated after 1 h of endotoxaemia. To quantify plasma extravasation across mesenteric venules, 50 mg/kg body weight of fluorescein isothiocyanate-labelled bovine serum albumin (FITC-BSA; Sigma) was injected 15 min before microscopy. The recorded fluorescent images were digitized and the grey levels were measured within five segments of the venule under study (Iv) and in five contiguous areas of the perivenular interstitium (Ip) depending on the fluorescence activity (grey levels ranged from 0 [black] to 255 [white]). Plasma extravasation (macromolecular leakage) was expressed as the ratio of Ip/Iv. Evaluation was performed in a blinded fashion.
PLASMA LEVELS OF CYTOKINES
To quantify the plasma cytokine levels, blood samples drawn at time points 0 h, 1.5 h and 3 h were immediately centrifuged at 4000 rpm (T54 centrifuge, MLW Medizintechnik, Leipzig, Germany) for 10 min. The plasma supernatant was stored at -84°C until TNF-α, IL-1β, IL-6 and IL-10 assays were performed. Concentrations of cytokines were measured using enzyme-linked immunosorbent assays (rat) according to the manufacturer's instructions (Biosource International, Camarillo, CA, USA).
STATISTICAL ANALYSIS
Data analysis was performed using statistical software packages (SPSS ® version 13; SPSS Inc., Chicago, IL, USA and SAS version 9.1; SAS Institute Inc., Cary, NC, USA). All data were expressed as group medians with 25th and 75th percentiles. The data were analysed with non-parametric tests in all cases due to the small sample sizes and after proving the data were not normally distributed and after proving equality of the variances. The Kruskal-Wallis test and the Mann-Whitney U-test were used to compare the groups at fixed time points. A multivariate nonparametric analysis of longitudinal data in factorial experiments, with adjustment for the baseline as a covariate, was adapted for analysis of repeat measurements. Therefore, the whole time course was taken into consideration simultaneously. Changes in interesting outcomes with respect to time J Birnbaum, E Klotz, CD Spies et al.
Combination therapy for endotoxaemia in rats
were analysed using non-parametric multivariate analysis of variance for repeat measurements in a two-factorial design (first factor, treatment [group 1 versus group 2]; second factor, repetitions in time). Therefore, we compared all of the time points simultaneously on the corresponding response curves. In the case of a significant difference existing between the LPS group and the treatment groups, a post-hoc analysis of covariance for pair-wise comparisons at each time point was performed. A P < 0.05 value was considered significant.
Results
The mean arterial pressure and heart rate for rats in the four study groups over the study duration are shown in Table 1 . Mean arterial pressure remained stable throughout in all animals, whereas heart rate significantly increased in all of the endotoxaemic groups after endotoxin challenge (P < 0.05). Administration of the drug combinations had no influence on mean arterial pressure or heart rate.
The count of firmly adherent leucocytes significantly increased (P < 0.05) following endotoxin challenge (Fig. 1) ; however, administration of both drug combinations resulted in a significant decrease in the count of firmly adherent leucocytes compared with the LPS group (P < 0.05). Rolling behaviour of leucocytes within the venules of the mesentery was not significantly influenced Table 2) .
Plasma extravasation across the mesenteric venules showed no inter-group differences. It increased over time in all groups, although there was some reduction in the drug treatment groups at 2 h compared with the level at 1 h, but this did not reach statistical significance compared with the LPS group (Table 3) .
Plasma levels of IL-1β are presented in Fig.  2 . They were significantly increased after endotoxin challenge (P < 0.05) but significantly reduced after administration of both drug combinations (P < 0.05). Plasma levels of IL-6 are presented in Fig. 3 . They were significantly increased after endotoxin challenge (P < 0.05) and the increase was significantly amplified in both drug treatment groups (P < 0.05). Plasma levels of TNF-α and IL-10 were both significantly increased after endotoxin challenge (P < 0.05), but were not influenced by the administration of either drug combination ( Table 4 ).
The WBC count was significantly decreased in the LPS group (P < 0.05) and in both drug treatment groups (P < 0.05) compared with the control group (Table 4 ). Neither of the drug combinations prevented the LPS-induced drop in WBC count.
Discussion
In this animal model of a septic state, we were able to induce some common Whereas in a previous study we found no reduction in leucocyte adherence in the submucosal venules with factor XIII administration alone, 24 the addition of C1-INH significantly attenuated leucocyte adherence (-35%) in submucosal venules compared with LPS group animals in our other animal model. 4 In the present study, the combination of C1-INH + factor XII reduced leucocyte adherence in the mesenteric venules to 31% of the values in the LPS group (-69%) at 1 h. This could indicate a synergistic effect from the combination of both substances, but it should be noted that leucocyte adherence was compared at different sites in the two different studies. In a pre-treatment model in endotoxaemic rats, NAC attenuated the increase in leucocyte adherence after endotoxin challenge to 50%. 26 The same effect was shown for pre-treatment with TM in the same sepsis model. 21 In our study, the combination of both substances reduced leucocyte adherence to as low as 22% of that seen in LPS animals at 1 h.
TABLE 2: Mean (range) count of temporarily adherent (rolling) leucocytes (leucocytes/min) in mesenteric venules at baseline (0 h), 1 h and 2 h after the start of endotoxaemia for the rats in the four study groups
In this study, we were not able to induce a significant increase in plasma extravasation by endotoxin challenge compared with the control group, although there was an increase in all groups. This correlates with the results of a former study, where we found no statistically significant difference in plasma extravasation across mesenteric venules between the CON and LPS groups using a comparable model (but a lower LPS dosage of 2.5 mg/kg per h). 24 In another study, we found an increase in plasma extravasation over time (2 h) in the CON and LPS groups compared with baseline but with no difference between the CON and LPS groups. 4 The amount of plasma extravasation depends on the LPS dosage and sometimes it varies with the batch of LPS, but it can be affected by the surgical manipulation of the animals (inflammatory response). We have previously shown an influence of drug administration on the elevated plasma extravasation, even though the increase in plasma extravasation could not definitely be attributed to the LPS challenge. 4 In the present study, the trend toward a reduction of plasma extravasation over time did not reach statistical significance. Although we have previously shown a reduction of plasma extravasation with C1-INH administration, 4 in another animal trial that involved factor XIII administration we could not show a reduction. 24 NAC reduced plasma extravasation in a comparable endotoxin model, 26 but an associated increased macromolecular leak was not influenced by TM pre-treatment. 21 In order to prove the influence of our experimental drug combinations on plasma extravasation in this animal model, a clear induction of increased plasma extravasation due to endotoxin challenge is essential.
Endotoxin challenge resulted in the expected increase in plasma levels of TNF-α, IL-1β, IL-6 and IL-10. While both drug combinations attenuated the increase of IL-1β plasma levels, post-hoc statistical analysis showed significance for the C1-INH + factor XIII group compared with the LPS group at 1.5 and 3 h suggesting a stronger effect than the effect of NAC + TM. The finding that both drug combinations amplified IL-6 release, even compared with the LPS group, was unexpected. So far, a reduction of IL-6 plasma levels by C1-INH during the inflammatory response in neonates has been shown. 27 We have not, however, been able to prove the influence of factor XIII alone (in a separate animal group) on IL-6 release in our animal model. Nevertheless, there is some evidence that patients carrying a Leu34 allele in the factor XIII-A subunit gene (associated J Birnbaum, E Klotz, CD Spies et al.
Combination therapy for endotoxaemia in rats
with more rapid factor XIII activation) have higher plasma levels of IL-6 compared with controls. 28 Since NAC is already known to reduce IL-6 plasma levels 29 -32 and since the antioxidant TM seems to have an inhibitory effect on IL-6 levels, 33 it is not obvious why the combination of both drugs induced an increase in IL-6 plasma levels. The elevated levels of TNF-α and IL-10 resulting from endotoxin challenge were not influenced by the administration of either drug combination in the present study. The LPSinduced reduction in WBC count was also not influenced by either drug combination.
The present study has some limitations and its results cannot be translated into the clinic without further investigation. In this setting, we were unable to prove if the combination of the drugs tested was superior to using them individually and a larger trial would be required for this. In addition, our study only suggests a possible beneficial effect without elucidating the underlying mechanisms. A dose-dependent effect of the drugs could also be possible, which might result in greater effects at higher doses. The doses we used, however, were the same as those administered in other experimental and clinical studies. 4, 18, 19, 24 In conclusion, in this sepsis model in rats, the combination of C1-INH + factor XIII as well as the combination of NAC + TM reduced both leucocyte-endothelium adherence and plasma levels of IL-1β. However, both drug combinations amplified the LPS-induced increase in plasma IL-6 levels, which suggests a possible proinflammatory effect of these therapies.
